FI20002612A0 - Combination therapy for the treatment of disorders in serotonin turnover - Google Patents
Combination therapy for the treatment of disorders in serotonin turnoverInfo
- Publication number
- FI20002612A0 FI20002612A0 FI20002612A FI20002612A FI20002612A0 FI 20002612 A0 FI20002612 A0 FI 20002612A0 FI 20002612 A FI20002612 A FI 20002612A FI 20002612 A FI20002612 A FI 20002612A FI 20002612 A0 FI20002612 A0 FI 20002612A0
- Authority
- FI
- Finland
- Prior art keywords
- disorders
- treatment
- combination therapy
- serotonin turnover
- serotonin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20002612A FI20002612A0 (en) | 2000-11-28 | 2000-11-28 | Combination therapy for the treatment of disorders in serotonin turnover |
AU2002218335A AU2002218335A1 (en) | 2000-11-28 | 2001-11-27 | Combination therapy for treatment of serotonergic disorders |
PCT/FI2001/001029 WO2002043724A1 (en) | 2000-11-28 | 2001-11-27 | Combination therapy for treatment of serotonergic disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20002612A FI20002612A0 (en) | 2000-11-28 | 2000-11-28 | Combination therapy for the treatment of disorders in serotonin turnover |
Publications (1)
Publication Number | Publication Date |
---|---|
FI20002612A0 true FI20002612A0 (en) | 2000-11-28 |
Family
ID=8559601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20002612A FI20002612A0 (en) | 2000-11-28 | 2000-11-28 | Combination therapy for the treatment of disorders in serotonin turnover |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002218335A1 (en) |
FI (1) | FI20002612A0 (en) |
WO (1) | WO2002043724A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003274185A1 (en) * | 2002-10-23 | 2004-05-13 | Orion Corporation | New uses of deramciclane |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU179164B (en) * | 1979-12-14 | 1982-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing cycloalkyl-ethers of alkanolamines |
HU226061B1 (en) * | 1996-10-17 | 2008-04-28 | Egis Gyogyszergyar Nyilvanosan | 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
EP1133986A1 (en) * | 2000-03-17 | 2001-09-19 | Orion Corporation | Use of deramciclane for the treatment of anxiety and depression |
-
2000
- 2000-11-28 FI FI20002612A patent/FI20002612A0/en unknown
-
2001
- 2001-11-27 WO PCT/FI2001/001029 patent/WO2002043724A1/en not_active Application Discontinuation
- 2001-11-27 AU AU2002218335A patent/AU2002218335A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2002218335A1 (en) | 2002-06-11 |
WO2002043724A1 (en) | 2002-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20005884D0 (en) | Combination therapy for the treatment of bipolar disorders | |
HK1152243A1 (en) | Vegf for use in the treatment of central nervous system disorders vegf | |
PT1147114E (en) | NEW ARALQUILAMINS OF UPRISING SPIROFUROPYRIDINES IN THERAPY. | |
IS6560A (en) | Pharmaceutical composition for the treatment of acute, persistent pain and / or nervous system pain and migraine | |
NO20044054L (en) | Administration of agents for the treatment of inflammation | |
CY2014005I2 (en) | TOPICAL GEL DELIVERY SYSTEMS FOR THE THERAPEUTIC TREATMENT OF SKIN DISORDERS | |
HK1092367A1 (en) | Combination therapy for the treatment of ocular neovascular disorders | |
DE60142473D1 (en) | INTRAKORPORAL MEDICAMENTS FOR THE PHOTODYNAMIC TREATMENT OF ILLNESSES | |
NO20041588L (en) | Use of flibanserin in the treatment of sexual disorders | |
NO20021845L (en) | Treatment of sleep disorders using desloratadine | |
ID30276A (en) | METHODS FOR TREATING SEXUAL DISORDERS | |
DK1702618T3 (en) | Use of ET743 in combination therapy with dexamethasone for the treatment of cancer | |
IS6137A (en) | Treatment of mental disorders | |
ZA200003236B (en) | Combination therapy for the treatment of migraine. | |
EE9900118A (en) | Use of H +, K + -ATPase Inhibitors in the Treatment of Nasal Polyps | |
NO20023448L (en) | Drug combination for the treatment of depression and related disorders including mirtazapine | |
ZA200110436B (en) | Therapeutic use of melatonin. | |
AU2003259246A8 (en) | Methods for the use of neurotoxin in the treatment of urologic disorders | |
NO20023803L (en) | Use of mirtazapine for the treatment of sleep disorders | |
NO20020784D0 (en) | Medication for the treatment of fractures | |
NO20043445L (en) | Combination therapy for the treatment of bacterial infections | |
PT1305307E (en) | EFFECTIVE INDOLE DERIVATIVES IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | |
EE200100527A (en) | Use of Osanetant in the preparation of medicaments useful for the treatment of mood disorders | |
NO20012612D0 (en) | Isonipecotamides for the treatment of integrin-mediated disorders | |
FI20002612A0 (en) | Combination therapy for the treatment of disorders in serotonin turnover |